Previous close | 34.85 |
Open | 34.85 |
Bid | 36.05 |
Ask | 42.90 |
Strike | 1,180.00 |
Expiry date | 2025-06-20 |
Day's range | 34.85 - 34.85 |
Contract range | N/A |
Volume | |
Open interest | 65 |
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Nvidia’s fight to remain the world’s most valuable company begins, disappointing retail sales raise hopes for a September rate cut, and more news to start your day.
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.